Real-World Utilization and Safety of Daratumumab IV Rapid Infusions Administered in a Community Setting: A Retrospective Observational Study

BACKGROUND: Some institutions have implemented a daratumumab intravenous rapid-infusion protocol in which patients with multiple myeloma (MM) receive their third and subsequent infusions within ~ 90 min instead of ≥ 3 h. OBJECTIVE: This study sought to understand the utilization, effectiveness, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordan, Lucio, Chang, Melody, Lafeuille, Marie-Hélène, Romdhani, Hela, Paramasivam, Fuad, Maiese, Eric M., McKay, Caroline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128966/
https://www.ncbi.nlm.nih.gov/pubmed/33565004
http://dx.doi.org/10.1007/s40801-020-00226-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128966/
https://www.ncbi.nlm.nih.gov/pubmed/33565004
http://dx.doi.org/10.1007/s40801-020-00226-3

Ejemplares similares